Oak Harvest Investment Services Bristol Myers Squibb CO Transaction History

Oak Harvest Investment Services

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 17, 2023	SELL	$63.71 - $70.74 $14,143 - $15,704	-222 Reduced 5.7%	3,674 $234,000
Q1 2023 Apr 20, 2023	SELL	$65.71 - $74.53 $43,105 - $48,891	-656 Reduced 14.41%	3,896 $270,000
Q4 2022 Jan 24, 2023	SELL	$68.48 - $81.09 $10,203 - $12,082	-149 Reduced 3.17%	4,552 $0
Q3 2022 Oct 14, 2022	SELL	$0.13 - $76.84 $6 - $4,072	-53 Reduced 1.11%	4,701 $334,000
Q2 2022 Jul 18, 2022	BUY	$72.62 - $79.98 $8,206 - $9,037	113 Added 2.43%	4,754 $366,000
Q1 2022 May 04, 2022	SELL	$61.48 - $73.72 $56,561 - $67,822	-920 Reduced 16.54%	4,641 $339,000
Q4 2021 Jan 21, 2022	BUY	$53.63 - $62.52 $9,170 - $10,690	171 Added 3.17%	5,561 $347,000
Q3 2021 Oct 08, 2021	SELL	$59.17 - $69.31 $37,040 - $43,388	-626 Reduced 10.41%	5,390 $319,000
Q2 2021 Jul 13, 2021	SELL	$61.91 - $67.42 $2.38 Million - $2.59 Million	-38,461 Reduced 86.47%	6,016 $402,000
Q1 2021 Apr 12, 2021	BUY	$59.34 - $66.74 $333,906 - $375,545	5,627 Added 14.48%	44,477 $2.81 Million
Q4 2020 Jan 15, 2021	BUY	$57.74 - $65.43 $2.24 Million - $2.54 Million	38,850 New	38,850 $2.41 Million

2,428

1.5B

29.7M

32.2M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $113B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Oak Harvest Investment Services, based on Form 13F filings with the SEC.

Stay updated on Oak Harvest Investment Services with notifications on news.